Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
Taking Esbriet (pirfenidone) to manage idiopathic pulmonary fibrosis (IPF) does not increase the risk of heart problems or interfere with commonly used cardiovascular medications, an analysis found. Results of ... Read more
When idiopathic pulmonary fibrosis (IPF) runs in families, it tends to begin earlier in life and be more severe, a recent study reported. The study,”Clinical characteristics of patients with ... Read more
A less toxic precursor formulation of the chemotherapeutic agent paclitaxel can reduce lung fibrosis in mice with pulmonary fibrosis, a study shows. The finding suggests that this compound, named ... Read more
The U.S. Food and Drug Administration has granted breakthrough therapy designation to PRM-151, a compound being investigated for the treatment of idiopathic pulmonary fibrosis (IPF). PRM-151 is a recombinant (lab-made) ... Read more
Pin It on Pinterest